5-Amino-1MQ

$
NNMT Inhibitor (non-peptide)

Investigational small molecule; Not a peptide

5-Amino-1MQ is included because peptide clinics and metabolic-stacking discussions often mention it, but chemically it is not a peptide. It is usually discussed as an NNMT inhibitor related to fat-cell metabolism and NAD salvage pathways.

Most claims are preclinical or early-stage. The main editorial note is categorization: do not present it as a peptide, and do not treat animal metabolic findings as proven human fat-loss outcomes. Ask why it is in a peptide guide at all. The answer is practical marketplace overlap, not chemical identity.

Look for human PK, dose-ranging, safety, liver markers, and objective body-composition data before drawing conclusions.

Classification details

  • 5-Amino-1MQ is investigated for NNMT inhibition and metabolic effects.
  • It is not FDA-approved as a drug.
  • 5-Amino-1MQ is a small-molecule NNMT inhibitor, not a peptide.
  • Proposed effects involve NNMT inhibition, NAD-related metabolism, adipose tissue biology, and energy expenditure.
  • Its proposed mechanism is NNMT inhibition, affecting NAD/methylation metabolism and adipocyte energy handling. This is pharmacology, not peptide-receptor signaling.

Sections 3-9, Works Cited, and the complete research guide require Full Access.

Get FULL Access and Guide
AOD-9604AdipotideSemaglutide

Educational reference only — not medical advice. Peptides discussed are not approved for human use in many jurisdictions and may be research-use-only. Consult a qualified clinician before use. Some detailed sections require full PepGuide access.